Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Adipotide and Semaglutide — mechanism, side effects, legal status, and pricing.
Adipotide (FTPP) is a chimeric peptidomimetic developed in the Arap/Pasqualini lab (originally at MD Anderson) that couples a 9-residue homing motif (CKGGRAKDC) — isolated by in vivo phage display as a ligand for prohibitin on white-adipose-tissue vasculature — to the D-amino-acid pro-apoptotic domain D(KLAKLAK)2. It is an experimental research compound, NOT FDA-approved for any indication. A clinical-development program in prostate-cancer-associated obesity reached early-phase testing and was ultimately discontinued.
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic (SubQ, type 2 diabetes), Wegovy (SubQ, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral, type 2 diabetes). It is a synthetic analog of native GLP-1 with a fatty-acid (C18 diacid) side chain that enables albumin binding, giving it a ~165-hour half-life suitable for once-weekly injection.
Adipotide
Semaglutide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Adipotide
Semaglutide
COA corpus from Disclosed Labs — independently tested batches only.
Adipotide
2
COAs
98.8%
Avg purity
2
Labs
Semaglutide
128
COAs
99.6%
Avg purity
13
Labs
Foundational proof-of-concept in obese mice (Kolonin et al., Nat Med 2004, PMID 15133506). A 4-week dosing study in spontaneously obese rhesus macaques showed substantial body-weight and fat-mass loss and improved insulin sensitivity but produced dose-dependent renal proximal-tubule toxicity (Barnhart et al., Sci Transl Med 2011, PMID 22072637). A small Phase 1 trial in obese prostate-cancer patients was initiated and later terminated; the program was permanently discontinued. No published human efficacy data. Grey-market human use is unstudied and carries documented nephrotoxicity risk.
The STEP program (STEP 1–8) showed average weight loss of roughly 15% of body weight over 68 weeks with weekly 2.4 mg semaglutide (STEP 1: Wilding et al., NEJM 2021, PMID 33567185). The SUSTAIN program established A1c and cardiovascular benefit in type 2 diabetes. The PIONEER program established efficacy of oral semaglutide (Rybelsus) versus placebo, sitagliptin, empagliflozin, and liraglutide (PIONEER 4, PMID 31186120). The SELECT trial (Lincoff et al., NEJM 2023, PMID 37952131) showed a 20% relative reduction in major adverse cardiovascular events in adults with overweight/obesity and established cardiovascular disease but without diabetes, leading to an expanded Wegovy indication.
Adipotide and Semaglutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs